欢迎来到《四川大学学报(医学版)》
羊裔明, 伍学强, 李健等. 清热解毒及活血化瘀中药治疗依赖泼尼松的慢性原发ITP患者的疗效观察[J]. 四川大学学报(医学版), 2016, 47(6): 969-970.
引用本文: 羊裔明, 伍学强, 李健等. 清热解毒及活血化瘀中药治疗依赖泼尼松的慢性原发ITP患者的疗效观察[J]. 四川大学学报(医学版), 2016, 47(6): 969-970.

清热解毒及活血化瘀中药治疗依赖泼尼松的慢性原发ITP患者的疗效观察

  • 摘要: 目的 观察以清热解毒及活血化瘀中药为主,治疗依赖泼尼松(prednisone,Pred)慢性原发免疫性血小板减少症(chronic primary immune thrombocytopenic purpura,CPITP)患者的疗效。方法 用以清热解毒及活血化瘀为主的中药门诊治疗对Pred依赖的CPITP患者,每天一剂,根据血小板数(blood platelet count, BPC)及临床出血情况,逐渐减少Pred的用量。合并中药治疗4周以上者,按中华血液学会提出的疗效标准评价加用中药前后的疗效,并比较加用中药前后BPC和Pred的用量。结果 50例Pred依赖CPITP经中药治疗后,BPC由治疗前的(28.6±22.5)×109 L-1升至(81.8±56.5)×109 L-1 (P<0.05); Pred的剂量由中药治疗前的(28.1±15.2) mg/d降到(8.0±9.4) mg/d(P<0.05);中药治疗前完全反应率、有效率和无效率分别为2%、10%和88%,中药治疗后上述指标分别为30%、46%、24% ( P<0.05)。结论 清热解毒及活血化瘀为主中药对依赖Pred的CPITP患者疗效显著,可增强患者对Pred的敏感性和克服对Pred的依赖。

     

    Abstract: Objective To observe the clinical efficacy of Qingre Jiedu and Huoxue Huayu Recipe on the prednisone-dependant patients with chronic primary immune thrombocytopenic purpura (CPITP). Methods Fifty prednisone-dependant CPITP patients were treated with Qingre Jiedu and Huoxue Huayu Recipe orally one dose a day, the dosage of prednisone for these patients was tapered according to the monitoring result of blood platelet count (BPC).The therapeutic efficacy in these patients was evaluated before and after Chinese medicine treatment over 4 weeks. Results After the treatment of chinese medicine, BPC was increased from (28.6±22.5) ×109 L-1 to (81.8±56.5)×109 L-1 (P<0.05). The dosage of prednisone was decreased from (28.1±15.2) mg/d to (8.0±9.4) mg/d (P<0.05). Complement response, response and no response rate were 2%, 10% and 88% before Chinese medicine treatment, which were 30%,46% and 24% after Chinese medicine treatment, respectively (P<0.05). Conclusion Qingre Jiedu and Huoxue Huayu Recipe could be effective in the treatment of prednisone-dependant patients with CPITP, and could decrease the dosage of prednisone.

     

© 2016 《四川大学学报(医学版)》编辑部 版权所有 cc

开放获取 本文遵循知识共享署名—非商业性使用4.0国际许可协议(CC BY-NC 4.0),允许第三方对本刊发表的论文自由共享(即在任何媒介以任何形式复制、发行原文)、演绎(即修改、转换或以原文为基础进行创作),必须给出适当的署名,提供指向本文许可协议的链接,同时标明是否对原文作了修改;不得将本文用于商业目的。CC BY-NC 4.0许可协议详情请访问 https://creativecommons.org/licenses/by-nc/4.0

/

返回文章
返回